References
- Paulson VA, Rudzinski ER, Hawkins DS. Thyroid Cancer in the Pediatric
Population. Genes (Basel). 2019; 10(9): 723.
- Verburg FA, Van Santen HM, Luster M. Pediatric papillary thyroid
cancer: current management challenges. Onco Targets Ther . 2016;
10: 165-175.
- Potter SL, Reuther J, Chandramohan R, et al. Integrated DNA and RNA
sequencing reveals targetable alterations in metastatic pediatric
papillary thyroid carcinoma. Pediatr Blood Cancer. 2021; 68(1):
e.28741.
- Lee YA, Lee H, Im Sun-Wha, et al. NTRK and RETfusion-directed therapy in pediatric thyroid cancer yields a tumor
response and radioiodine uptake. J Clin Invest . 2021; 131(18):
e144847.
- Wirth JL, Sherman E, Robinson B, et al. Efficacy of Selpercatinib in
RET-Altered Thyroid Cancers. N Engl J Med. 2020; 383(9):
825-835.
- Bradford D, Larkins E, Mushti SL, et al. FDA Approval Summary:
Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET
Gene Mutations or Fusions. Clinical Cancer Research . 2021;
27(8): 2130-2135.
- Ortiz MV, Gerdemann U, Govinda S, et al. Selpercatinib (LOXO-292) in
Pediatric Patients With Tumors Harboring RET Gene Alterations.JCO Precis Oncol . 2020; 4: PO.19.00401.
- Shankar A, Kurzawinski T, Ross E, et al. Treatment outcome with a
selective RET tyrosine kinase inhibitor selpercatinib in
children with multiple endocrine neoplasia type 2 and advanced
medullary thyroid carcinoma. Eur J Cancer . 2021; 158:38-46.
- Morgenstern DA, Mascarenhas L, Campbell M, et al. Oral selpercatinib
in pediatric patients with advanced RET -altered solid or
primary CNS tumors: Preliminary results from the phase 1/2
LIBRETTO-121 trial. J Clin Oncol . 2021; 39: 15_suppl, 10009.
- Reiners C, Demidchik YE. Differentiated thyroid cancer in childhood:
pathology, diagnosis, therapy. Pediatric Endocrinol Rev . 2003;
Suppl 2: 230-5.
- Dinauer CA, Breuer C, Rivkees SA. Differentiated thyroid cancer in
children: diagnosis and management. Curr Opin Oncol . 2008;
20(1): 59-65.
- Markovina S, Grigsby PW, Schwarz JK, et al. Treatment approach,
surveillance, and outcome of well-differentiated thyroid cancer in
childhood and adolescence. Thyroid. 2014; 24(7):1121-6.
- Albano D, Bertagna F, Panarotto MB, Giubbini R. Early and late adverse
effects of radioiodine for pediatric differentiated thyroid cancer.Pediatr Blood Cancer . 2017; 64(11): doi:10.1002
- Pawelczak M, David R, Franklin B, Kessler M, Lam L, Shah B. Outcomes
of children and adolescents with well-differentiated thyroid carcinoma
and pulmonary metastases following 131I treatment: a
systematic review. Thyroid . 2010; 20(10): 1095-101.
- Santoro M, Moccia M, Federico G, Carlomagno F. RET Gene Fusions in
Malignancies of the Thyroid and Other Tissues. Genes (Basel).2020; 11(4): 424.
- Thein KZ, Velcheti V, Mooers BHM, Wu J, Subbiah V. Precision therapy
for RET- altered cancers with RET inhibitors. Trends
Cancer . 2021; 7(12): 1074-1088.
- Salvatore D, Santoro M, Schlumberger M. The importance of the RET gene
in thyroid cancer and therapeutic implications. Nat Rev
Endocrinol . 2021; 17(5): 296-306.
- Tsang V, Gill A, Gild M, et al. Selpercatinib Treatment ofRET -Mutated Thyroid Cancers Is Associated With Gastrointestinal
Adverse Effects. J Clin Endocrinol Metab . 2022;
107(9):e3824-e3829.
- Bellantoni AJ, Wagner LM. Purusing Precision: Receptor Tyrosine Kinase
Inhibitors for Treatment of Pediatric Solid Tumors. Cancers
(Basel) . 2021; 13(14): 3531.